Flagship Pioneering-founded Generate Biomedicines is tacking on a gigantic $273 million in series C funds, though the haul didn't reach the heights of the biotech’s previous $370 million raise back in ...
Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence signals.
Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis. The wide-ranging deal, worth up to $1 billion, ...
As part of its mission to open new sources of capital for the clean energy transition, Generate has deepened partnerships with insurance companies, pension plans and existing shareholders seeking ...
Generate Biomedicines, which uses artificial intelligence for protein design, recently opened a cryo-electron microscopy (cryo-EM) laboratory in Andover, Massachusetts, that it says will accelerate ...
Generate Biomedicines is setting out to “program” medicine by almost instantaneously creating models of new proteins. Launched out of life sciences venture firm Flagship Pioneering, it raised a large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results